Zentalis Pharmaceuticals, Inc. Stock Price, News & Analysis

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has announced a proposed underwritten public offering of $150 million in shares of common stock, all to be sold by the company. Additionally, Zentalis may grant underwriters a 30-day option to purchase up to an additional $22.5 million in shares. The offering is being managed by Morgan Stanley, Jefferies, SVB Leerink, and Guggenheim Securities. This offering follows an effective shelf registration statement filed with the SEC on May 4, 2020. A preliminary prospectus supplement will soon be available on the SEC’s website.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported promising interim data from the Phase 1 trial of ZN-c3, a WEE1 inhibitor, showing increased tumor reduction and durability in heavily pretreated solid tumors. The FDA has identified a potential accelerated approval pathway for ZN-c3 in uterine serous carcinoma (USC), with multiple clinical trials underway including a registrational study. ZN-c3 also received orphan drug and rare pediatric disease designations for osteosarcoma. Concurrently, ZN-c5 shows best-in-class safety and tolerability in breast cancer treatments.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced participation in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 2:30 p.m. ET. Anthony Sun, MD, Chairman and CEO, along with Melissa Epperly, CFO, will represent the company. Interested parties can access the live webcast through the Investors section of Zentalis' website, with an archived version available post-event. Zentalis focuses on developing small molecule therapeutics targeting cancer biology, including candidates like ZN-c5 and ZN-c3.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported encouraging initial results from the Phase 1 trial of its WEE1 inhibitor, ZN-c3, demonstrating single-agent activity and multiple Exceptional Responses in heavily pre-treated cancer patients. The company has entered a clinical collaboration with GSK to explore ZN-c3 in combination with niraparib. For Q1 2021, Zentalis had cash and securities of $298.4 million, but reported a net loss of $50.4 million, up from $16.2 million in Q1 2020 due to increased R&D costs.

Zentalis Pharmaceuticals announced a clinical collaboration with GlaxoSmithKline to evaluate ZN-c3, Zentalis' oral WEE1 inhibitor, in combination with ZEJULA (niraparib) for advanced ovarian cancer. This partnership aims to explore the enhanced potential of ZN-c3 as part of combination therapy, potentially improving patient outcomes. ZN-c3 is currently involved in various trials, with significant preclinical data supporting its efficacy. Over 300,000 women are diagnosed with ovarian cancer annually, highlighting the need for innovative treatments. Zentalis retains full ownership of ZN-c3.

Zentalis Pharmaceuticals announced promising initial data from the Phase 1 trial of ZN-c3, a WEE1 inhibitor, showing Exceptional Responses in patients with advanced solid tumors, including ovarian and colorectal cancer. The recommended Phase 2 dose has been set at 300 mg QD. Out of 55 patients, the treatment was well-tolerated, with manageable side effects primarily Grade 1/2. A webcast event is scheduled for April 12 to discuss these findings further.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported its fourth quarter and full-year financial results for 2020, highlighting pivotal advancements in its oncology pipeline and strategic collaborations. As of December 31, 2020, the company had cash and marketable securities of approximately $338.5 million, enabling operations into 2023. Significant increases in research and development expenses reached $29.5 million in Q4 2020. The net loss for Q4 2020 was $40.4 million, compared to $14.5 million in the previous year.

Key developments included the initiation of multiple early-stage clinical trials and a collaboration with Tempus to enhance research capabilities.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced three accepted abstracts for the AACR Annual Meeting 2021, including a late-breaking presentation on its WEE1 inhibitor, ZN-c3. The meeting will occur virtually from April 10-15 and May 17-21, 2021. Highlights include:

• A late-breaker session on the clinical activity of ZN-c3 in advanced solid tumors.
• Poster presentations on ZN-c3's selectivity and ZN-e4's anti-tumor effects in EGFR mutant lung cancer.

Data supports Zentalis' ability to differentiate its oncology therapeutic candidates.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) has announced a strategic collaboration with Tempus to enhance its research capabilities. This partnership will utilize Tempus' patient-derived organoid biological modeling platform, mainly to evaluate Zentalis' WEE1 inhibitor, ZN-c3, for its effectiveness in various cancer treatments. ZN-c3 aims to induce DNA damage in cancer cells to inhibit tumor growth. The collaboration will help identify patient populations most likely to benefit from ZN-c3, positioning Zentalis favorably for clinical advancements.